Skip to main content
Top

Open Access 25-04-2024 | Glioma | CLINICAL GUIDES IN ONCOLOGY

SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)

Authors: María Ángeles Vaz-Salgado, Belén Cigarral García, Isaura Fernández Pérez, Beatriz Jiménez Munárriz, Paula Sampedro Domarco, Ainhoa Hernández González, María Vieito Villar, Raquel Luque Caro, María Luisa Villamayor Delgado, Juan Manuel Sepúlveda Sánchez

Published in: Clinical and Translational Oncology

Login to get access

Abstract

The 2021 World Health Organization (WHO) classification has updated the definition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by surgery and complementary treatments are vital to improving prognosis. This guideline provides recommendations on the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas based on the best evidence available.
Literature
10.
go back to reference Dykewicz CA, Centers for Disease Control and Prevention (U.S.), Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139–44. https://doi.org/10.1086/321805.CrossRefPubMed Dykewicz CA, Centers for Disease Control and Prevention (U.S.), Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139–44. https://​doi.​org/​10.​1086/​321805.CrossRefPubMed
20.
go back to reference Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015;129(5):679–93. https://doi.org/10.1007/s00401-015-1409-0.CrossRefPubMed Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015;129(5):679–93. https://​doi.​org/​10.​1007/​s00401-015-1409-0.CrossRefPubMed
25.
go back to reference Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol. 2006;24(18):2707–14. https://doi.org/10.1200/JCO.2005.04.3414.CrossRef Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol. 2006;24(18):2707–14. https://​doi.​org/​10.​1200/​JCO.​2005.​04.​3414.CrossRef
26.
go back to reference van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJB, Bernsen HJJA, et al. Adjuvant Procarbazine, lomustine, and Vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol. 2006;24(18):2715–22. https://doi.org/10.1200/JCO.2005.04.6078.CrossRefPubMed van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJB, Bernsen HJJA, et al. Adjuvant Procarbazine, lomustine, and Vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol. 2006;24(18):2715–22. https://​doi.​org/​10.​1200/​JCO.​2005.​04.​6078.CrossRefPubMed
37.
go back to reference Zhang Z-Y, Chan AK-Y, Ng H-K, Ding X-J, Li Y-X, Shi Z-F, et al. Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. Int J Clin Exp Pathol. 2014;7(12):8627–36.PubMedPubMedCentral Zhang Z-Y, Chan AK-Y, Ng H-K, Ding X-J, Li Y-X, Shi Z-F, et al. Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. Int J Clin Exp Pathol. 2014;7(12):8627–36.PubMedPubMedCentral
44.
go back to reference Karim ABMF, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the medical research council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2022;52(2):316–24. https://doi.org/10.1016/s0360-3016(01)02692-x.CrossRef Karim ABMF, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the medical research council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2022;52(2):316–24. https://​doi.​org/​10.​1016/​s0360-3016(01)02692-x.CrossRef
45.
go back to reference Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J Clin Oncol. 2002;20(9):2267–76. https://doi.org/10.1200/JCO.2002.09.126.CrossRefPubMed Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J Clin Oncol. 2002;20(9):2267–76. https://​doi.​org/​10.​1200/​JCO.​2002.​09.​126.CrossRefPubMed
47.
go back to reference Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, et al. Comprehensive genomic analysis in NRG oncology/RTOG 9802: a phase III trial of radiation versus radiation plus Procarbazine, lomustine (CCNU), and Vincristine in high-risk low-grade glioma. J Clin Oncol. 2010;38(29):3407–17. https://doi.org/10.1200/JCO.19.02983.CrossRef Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, et al. Comprehensive genomic analysis in NRG oncology/RTOG 9802: a phase III trial of radiation versus radiation plus Procarbazine, lomustine (CCNU), and Vincristine in high-risk low-grade glioma. J Clin Oncol. 2010;38(29):3407–17. https://​doi.​org/​10.​1200/​JCO.​19.​02983.CrossRef
Metadata
Title
SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)
Authors
María Ángeles Vaz-Salgado
Belén Cigarral García
Isaura Fernández Pérez
Beatriz Jiménez Munárriz
Paula Sampedro Domarco
Ainhoa Hernández González
María Vieito Villar
Raquel Luque Caro
María Luisa Villamayor Delgado
Juan Manuel Sepúlveda Sánchez
Publication date
25-04-2024
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-024-03456-x
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare